Sonoma Pharmaceuticals, Inc.

Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) resulting from allegations that Sonoma may have issued materially misleading business information to the investing public.

If you purchased Sonoma securities and would like to join the prospective action, please click “Join This Class Action.”

If you purchased Sonoma securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Details of investigation:

On November 17, 2020, after market hours, Sonoma filed a Form 8-K with the U.S. Securities and Exchange Commission announcing that Sonoma’s “unaudited condensed consolidated interim financial statements for the quarter ended June 30, 2020 should no longer be relied upon.” Sonoma continued that the financial statements for this time period “contained material errors” and that “the Company will need to restate them.”

On this news, Sonoma’s share price fell $1.10 per share, or more than 14%, over the next few trading days to close at $6.63 per share on November 20, 2020.

Attorney Advertising. Prior results do not guarantee a similar outcome.

公司名称: Sonoma Pharmaceuticals, Inc.
股票代号: SNOA
集体诉讼期: N/A
法院: N/A


自 2013 年以来,罗森律师事务所每年都是代表投资者成功提起证券集体诉讼的前四大律所之一。仅 2019 年,本律所就为投资者追回 4.38 亿美元资金。


机构股东服务公司按 2017 年证券集体诉讼索赔数量,罗森律师事务所列为第一名。